North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) - Forecast to 2017

NEW YORK, April 22, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Forecast to 2017
http://www.reportlinker.com/p01163147/North-American-Nuclear-Medicine/Radiopharmaceuticals--Stable-Isotopes-Market-[SPECT/PET-Radioisotopes-Technetium-F-18]-[Beta/Alpha-Radiation-Therapy-I131-Y-90]-[Applications-Cancer/Oncology-Cardiac]--Deuterium-C-13-–--Forecast-to-2017 .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging

The North American radiopharmaceuticals market was valued at $1.9 billion in 2012 and is poised to reach $2.7 billion by 2017 at a CAGR of 7.2%.

A study conducted by Organization for Economic Co-operation and Development (OECD) estimates that Tc-99m diagnostic procedures are expected to increase by 15% to 20% in mature markets such as North America between 2010 and 2030. Radiopharmaceuticals in neurological applications such as Alzheimer's disease, Parkinson's disease, and dementia are also being preferred by practitioners besides conventional treatment. Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. The scheduled shutdown of the NRU reactor in 2016 in Canada is, however, a major threat for manufacturers.

The therapy market is predominantly driven by its oncologic applications. Since conventional treatment procedures of cancer, surgery and chemotherapy have significant side effects; radioisotopes are being preferred by medical practitioners due to minimum or no side effects. The radiopharmaceutical therapy market is expected to grow significantly with the launch of the much-desired Alpharadin (Ra-223) in the near future. This isotope has tremendous potential to take up market share of beta emitters and brachytherapy.

The U.S. is the dominant market for diagnostic radioisotopes with more than 80% share. The U.S. is the largest consumer market for radiopharmaceuticals in North America, while Canada is one of the largest producers of Tc-99m. Major players in the radiopharmaceuticals market are Cardinal Health, Inc. (U.S.), Lantheus Medical Imaging, Inc. (U.S.), Nordion, Inc. (Canada), and Triad Isotopes, Inc. (U.S.).

The stable isotopes market was led by two players - Cambridge Isotope Laboratories (CIL) and Sigma Aldrich - in 2012; they jointly contributed more than 90% to the North American revenue.

Scope of the Report

The radioisotope and stable isotope markets have been segmented according to the type of isotope, and applications. Both of these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by country (U.S. and Canada) to provide in-depth information on the country basis.

North American Radiopharmaceuticals Market

 

Diagnostic
SPECT
Tc-99m
Tl-201
Ga-67
I-123
Others
PET
F-18
Rb-82
Others
Therapy
Beta emitters
I-131
Sm-153
Re-186
Y-90
Lu-177
Others
Alpha emitters
Brachytherapy
Cs-131
I-125
Pd-103
Ir-192
Others

North American Enriched Stable Isotopes Market

Deuterium
Oxygen-18
Carbon-13
Nitrogen-15
Others

North American Radiopharmaceutical and Stable Isotope Markets, By Country

U.S.
Canada

TABLE OF CONTENTS

1 INTRODUCTION 26

1.1 KEY TAKE-AWAYS 26
1.2 REPORT DESCRIPTION 26
1.3 MARKETS COVERED 28
1.4 STAKEHOLDERS 29
1.5 RESEARCH METHODOLOGY 30
1.5.1 MARKET SIZE 30
1.5.2 MARKET SHARE 30
1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES 31
1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES 31
1.5.5 ASSUMPTIONS 32

2 EXECUTIVE SUMMARY 33

3 MARKET OVERVIEW 37

3.1 DEFINITION OF RADIOPHARMACEUTICALS 38
3.2 EVOLUTION 38
3.3 MARKET SEGMENTATION 40
3.3.1 RADIOPHARMACEUTICALS 40
3.3.2 STABLE ISOTOPES 41
3.4 MARKET DYNAMICS 42
3.4.1 DRIVERS 43
3.4.1.1 Increasing incidence of cancer and cardiac ailments boosts the demand for radiopharmaceuticals 43
3.4.1.2 Increasing use of SPECT and PET scans results in the rise of radiopharmaceutical usage 43
3.4.1.3 Rising awareness of radiopharmaceuticals to spur growth 44
3.4.1.4 Ready availability of radiopharmaceuticals from cyclotrons to goad the growth 44
3.4.2 RESTRAINTS 44
3.4.2.1 Shorter half-life of radiopharmaceuticals to restrict usage 44
3.4.2.2 High capital demand to limit the buying of scanners 45
3.4.2.3 Stringent regulatory guidelines and GMP to negatively impact growth 45
3.4.2.4 Competition from conventional diagnostic procedures 46
3.4.3 OPPORTUNITIES 47
3.4.3.1 Ample number of potential radioisotopes in the pipeline 47
3.4.3.2 Alpha radioimmunotherapy-based targeted cancer treatment 47
3.4.3.3 Alternative diagnostic radiopharmaceuticals solution 48
3.4.3.4 Cyclotron-based production 48
3.4.3.5 Neurological application 48
3.4.4 THREAT 49
3.4.4.1 Shutdown of nuclear reactors impacts the production of radioisotopes 49
3.5 WINNING IMPERATIVES 50
3.5.1 INVESTMENT TO ENCOURAGE NEW RADIOISOTOPES AND NOVEL APPLICATIONS 50
3.5.2 SHIFT TOWARDS LEU BASED MO-99 PRODUCTION 50
3.6 BURNING ISSUES 51
3.6.1 HIGH COST OF PET CAMERAS 51
3.6.2 SHORTAGE IN SUPPLY OF TECHNETIUM-99M 51
3.7 SUPPLY AND DEMAND ANALYSIS OF TECHNETIUM-99M 52
3.8 REGULATORY AFFAIRS 53
3.8.1 U.S. 53
3.8.1.1 FDA Approval Process 54
3.8.1.2 Transportation 54
3.8.1.3 Reimbursement scenario 55
3.8.2 CANADA 55
3.8.2.1 Nuclear Safety and Control Act 55
3.8.2.2 Transportation 56
3.8.2.3 Licensing 56
3.9 MARKET SHARE ANALYSIS 57
3.9.1 RADIOPHARMACEUTICALS MARKET 57
3.9.2 ENRICHED STABLE ISOTOPES MARKET 60

4 NORTH AMERICAN RADIOPHARMACEUTICALS MARKET, BY ISOTOPE 61

4.1 INTRODUCTION 62
4.2 DIAGNOSTIC ISOTOPES 62
4.2.1 OPPORTUNITY MATRIX 63
4.2.2 SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) RADIOPHARMACEUTICALS 65
4.2.2.1 Technetium-99m (Tc-99m) 67
4.2.2.1.1 Tc-99m to decide growth trend of SPECT radioisotopes 69
4.2.2.1.2 Factors affecting Technetium-99m market 70
4.2.2.1.2.1 Technetium can combine with 31 different carrier molecules 70
4.2.2.1.2.2 Lack of availability of technetium 70
4.2.2.2 Thallium-201 (Tl-201) 70
4.2.2.2.1 Tl-201 is a potential substitute for Tc-99m 71
4.2.2.3 Gallium-67 (Ga-67) 72
4.2.2.3.1 Fluorine-18 might seize Ga-67 market share in the near future 72
4.2.2.4 Iodine (I-123) 73
4.2.2.5 Others 74
4.2.3 POSITRON EMISSION TOMOGRAPHY (PET) RADIOPHARMACEUTICALS 76
4.2.3.1 Fluorine-18 79
4.2.3.1.1 FDG 79
4.2.3.1.2 Florbetapir 79
4.2.3.1.3 Factors affecting Fluorine-18 market 81
4.2.3.1.3.1 Increasing availability of PET machines 81
4.2.3.1.3.2 Rise in PET procedures increases demand for FDG 81
4.2.3.1.3.3 High generation costs of FDG 81
4.2.3.1.3.4 Need for speedy & efficient transportation 81
4.2.3.2 Rubidium-82 (Rb-82) 82
4.2.3.2.1 Bracco re-launched CardioGen-82 in
February 2012 82
4.2.3.3 Others 83
4.2.3.3.1 Ga-68 deemed as a potential PET radioisotope 83
4.3 THERAPEUTIC ISOTOPES 85
4.3.1 OPPORTUNITY MATRIX 86
4.3.2 BETA EMITTERS 87
4.3.2.1 Iodine-131 (I-131) 89
4.3.2.2 Yttrium-90 (Y-90) 90
4.3.2.2.1 Y-90 market influenced by popularity of Nordion's TheraSphere 90
4.3.2.3 Samarium-153 (Sm-153) 91
4.3.2.4 Rhenium-186 (Re-186) 93
4.3.2.5 Lutetium-177 (Lu-177) 94
4.3.2.5.1 Lu-177 is a potential treatment option for neuroendocrine cancer 94
4.3.2.6 Others 95
4.3.2.6.1 Re-188 and P-33 are notable promising isotope 95
4.3.3 ALPHA EMITTERS 96
4.3.3.1 Radium-223 (Ra-223)&Alpharadin 97
4.3.3.1.1 Successful completion of Phase III trials in men with bone metastases from CRPC 99
4.3.3.1.2 First in-class alpha pharmaceutical 99
4.3.3.1.3 Alpharadin is advantageous over Taxotere, beta-therapy and brachytherapy 99
4.3.3.1.4 Success of Alpharadin 100
4.3.3.1.5 Porter's five forces analysis 100
4.3.3.1.6 SWOT Analysis 101
4.3.3.2 Actinium-225 (Ac-225) 102
4.3.3.3 Lead-212 (Pb-212)/Bismuth-212 (Bi-212) 103
4.3.3.4 Astatine-211 (At-211) 103
4.3.3.5 Radium-224 (Ra-224) 103
4.3.3.6 Thorium-227 (Th-227) 103
4.3.4 BRACHYTHERAPY 104
4.3.4.1 U.S. to show slow growth due to reimbursement issues 106
4.3.4.2 Cesium-131 108
4.3.4.3 Iodine-125 109
4.3.4.4 Palladium-103 110
4.3.4.5 Iridium-192 111
4.3.4.6 Others 112

5 NORTH AMERICAN RADIOPHARMACEUTICALS MARKET, BY APPLICATION/INDICATIONS 113

5.1 INTRODUCTION 114
5.2 DIAGNOSTIC APPLICATION 114
5.2.1 SPECT 115
5.2.1.1 Cardiology 117
5.2.1.2 Lymphoma 118
5.2.1.3 Thyroid 119
5.2.1.4 Neurology 120
5.2.1.4.1 Alzheimer's, dementia, and Parkinson's disease drive growth of the neurology SPECT market 120
5.2.1.5 Others 121
5.2.2 PET 122
5.2.2.1 Oncology 123
5.2.2.1.1 FDG F-18 has become a gold standard for oncology diagnosis using PET scan 123
5.2.2.2 Cardiology 124
5.2.2.3 Neurology 125
5.2.2.3.1 Florbetapir F-18 & Fluorodopa (F-18 dopa) are potential substitutes of FDG F-18 125
5.2.2.4 Others 126
5.3 THERAPEUTIC APPLICATION 128
5.3.1 THYROID 129
5.3.2 BONE METASTASIS 130
5.3.3 LYMPHOMA 132
5.3.3.1 Novel clinical studies goading lymphoma therapy market 132
5.3.4 ENDOCRINE TUMORS 133
5.3.5 OTHERS 134

6 NORTH AMERICAN ENRICHED STABLE ISOTOPES MARKET 136

6.1 INTRODUCTION 137
6.2 MARKET OVERVIEW 138
6.3 MARKET DYNAMICS 139
6.3.1 DRIVERS 139
6.3.1.1 Stable isotopes are natural in origin & hence safe 139
6.3.1.2 Proteomics & system biology, major factors to boost the growth of stables 139
6.3.1.3 Medical applications propel stable isotopes market growth 139
6.3.2 RESTRAINTS 140
6.3.2.1 Harmful effects of high doses of stable isotopes affect market growth 140
6.3.2.2 High cost of stables isotope 140
6.4 ENRICHED STABLES MARKET, BY ISOTOPE 141
6.4.1 DEUTERIUM & O-18 ARE PROMISING ISOTOPES 142
6.4.2 CARBON-13 144
6.4.3 DEUTERIUM 145
6.4.4 OXYGEN-18 146
6.4.5 NITROGEN-15 147
6.4.6 OTHER STABLE ISOTOPES 148
6.5 ENRICHED STABLES MARKET, BY APPLICATION 149
6.5.1 DIAGNOSTIC & THERAPEUTIC 150
6.5.2 RESEARCH 150
6.5.3 PHARMACEUTICAL 152
6.5.4 INDUSTRIAL SECTOR 152

7 GEOGRAPHIC ANALYSIS 154

7.1 INTRODUCTION 155
7.2 U.S. 167
7.2.1 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET 167
7.2.2 THERAPEUTIC RADIOPHARMACEUTICALS MARKET 170
7.2.3 STABLE ISOTOPE MARKET 173
7.3 CANADA 175
7.3.1 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET 175
7.3.2 THERAPEUTIC RADIOPHARMACEUTICALS MARKET 178
7.3.3 STABLE ISOTOPE MARKET 181

8 COMPETITIVE LANDSCAPE 183

8.1 INTRODUCTION 183
8.2 MERGERS & ACQUISITIONS 184
8.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS &
JOINT VENTURES 185
8.4 PRODUCTS LAUNCH 189
8.5 EXPANSIONS 190
8.6 OTHER DEVELOPMENTS 192
8.7 APPROVALS 194

9 COMPANY PROFILES 195

9.1 COMPANIES 195
9.1.1 BRACCO IMAGING S.P.A. 195
9.1.2 CAMBRIDGE ISOTOPE LABORATORIES, INC. 197
9.1.3 CARDINAL HEALTH, INC. 201
9.1.4 COVIDIEN, PLC 208
9.1.5 ECZACIBASI-MONROL 213
9.1.6 FUJIFILM HOLDINGS CORPORATION 215
9.1.7 GE HEALTHCARE (SUBSIDIARY OF GENERAL ELECTRIC COMPANY) 220
9.1.8 IBA GROUP 225
9.1.9 ISOTEC, INC. (SIGMA-ALDRICH) 231
9.1.10 LANTHEUS MEDICAL IMAGING, INC. 235
9.1.11 NORDION, INC. 243
9.1.12 NTP RADIOISOTOPES (PTY), LTD. 250
9.1.13 PETNET SOLUTIONS, INC. (A SUBSIDIARY OF SIEMENS MEDICAL SOLUTIONS USA, INC.) 253
9.1.14 TAIYO NIPPON SANSO CORPORATION 258
9.1.15 TRIAD ISOTOPES, INC. 261
9.1.16 URENCO LIMITED 264
9.1.17 ROTEM INDUSTRIES, LTD., INC. 268
9.2 INSTITUTES 270
9.2.1 AUSTRALIAN NUCLEAR ASSOCIATION AND TECHNOLOGY ORGANIZATION (ANSTO) 270
9.2.2 BOARD OF RADIATION AND ISOTOPE TECHNOLOGY (BRIT) 272
9.2.3 INSTITUTE OF ATOMIC ENERGY POLATOM RADIOISOTOPE CENTRE 274
9.2.4 INSTITUTE OF ISOTOPES CO., LTD. 276
9.2.5 INSTITUTE OF RADIOELEMENT (IRE) 279

LIST OF TABLES

TABLE 1 NORTH AMERICA: DIAGNOSTIC RADIOPHARMACEUTICALS MARKET,
BY TECHNOLOGY, 2010 – 2017 ($MILLION) 34
TABLE 2 NORTH AMERICA: RADIOIPHARMACEUTICALS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 35
TABLE 3 NORTH AMERICA: DIAGNOSTIC RADIOPHARMACEUTICALS MARKET,
BY TECHNOLOGY, 2010 – 2017 ($MILLION) 63
TABLE 4 NORTH AMERICA: SPECT RADIOPHARMACEUTICALS MARKET,
BY ISOTOPE, 2010 – 2017 ($MILLION) 66
TABLE 5 NORTH AMERICA: SPECT RADIOPHARMACEUTICALS MARKET,
BY COUNTRY, 2010 – 2017 ($MILLION) 67
TABLE 6 INDICATIONS DIAGNOSED BY TC-99M 68
TABLE 7 NORTH AMERICA: TC-99M MARKET, BY COUNTRY,
2010- 2017 ($MILLION) 69
TABLE 8 NORTH AMERICA: TL-201 MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 71
TABLE 9 NORTH AMERICA: GA-67 MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 73
TABLE 10 NORTH AMERICA: I-123 MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 74
TABLE 11 NORTH AMERICA: OTHER RADIOPHARMACEUTICALS MARKET,
BY COUNTRY, 2010 – 2017 ($MILLION) 75
TABLE 12 NORTH AMERICA: PET RADIOPHARMACEUTICALS MARKET,
BY COUNTRY, 2010 – 2017 ($MILLION) 77
TABLE 13 NORTH AMERICA: PET RADIOPHARMACEUTICALS MARKET,
BY ISOTOPE, 2010 – 2017 ($MILLION) 78
TABLE 14 NORTH AMERICA: F-18 MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 80
TABLE 15 NORTH AMERICA: RB-82 MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 82
TABLE 16 NORTH AMERICA: OTHER PET RADIOPHARMACEUTICALS MARKET,
BY COUNTRY, 2010 – 2017 ($MILLION) 84
TABLE 17 NORTH AMERICA: THERAPEUTIC RADIOPHARMACEUTICALS MARKET,
BY TECHNOLOGY 2010 – 2017 ($MILLION) 85
TABLE 18 NORTH AMERICA: BETA EMITTERS MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 88
TABLE 19 NORTH AMERICA: BETA EMITTER RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 89
TABLE 20 NORTH AMERICA: I-131 MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 90
TABLE 21 NORTH AMERICA: Y-90 MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 91
TABLE 22 NORTH AMERICA: SM-153 MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 92
TABLE 23 NORTH AMERICA: RE-186 MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 93
TABLE 24 NORTH AMERICA: LU-177 MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 95
TABLE 25 NORTH AMERICA: OTHER BETA EMITTERS MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 96
TABLE 26 ALPHA EMITTERS VS BETA EMITTERS 97
TABLE 27 RADIOISOTOPE CHARACTERISTICS & DOSE DELIVERY OVER TIME 104
TABLE 28 NORTH AMERICA: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 106
TABLE 29 NORTH AMERICA: BRACHYTHERAPY MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 107
TABLE 30 NORTH AMERICA: CS-131 MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 108
TABLE 31 NORTH AMERICA: I-125 MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 109
TABLE 32 NORTH AMERICA: PD-103 MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 110
TABLE 33 NORTH AMERICA: IR-192 MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 111
TABLE 34 NORTH AMERICA: OTHER BRACHYTHERAPY MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 112
TABLE 35 NORTH AMERICA: SPECT APPLICATION MARKET,
2010 – 2017 ($MILLION) 116
TABLE 36 NORTH AMERICA: CARDIOLOGY SPECT MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 117
TABLE 37 NORTH AMERICA: LYMPHOMA SPECT MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 118
TABLE 38 NORTH AMERICA: THYROID SPECT MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 119
TABLE 39 NORTH AMERICA: NEUROLOGY SPECT MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 120
TABLE 40 NORTH AMERICA: OTHER SPECT APPLICATIONS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 121
TABLE 41 NORTH AMERICA: PET MARKET, BY APPLICATION,
2010 – 2017 ($MILLION) 122
TABLE 42 NORTH AMERICA: ONCOLOGY PET MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 123
TABLE 43 NORTH AMERICA: CARDIOLOGY PET MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 124
TABLE 44 NORTH AMERICA: NEUROLOGY PET MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 126
TABLE 45 NORTH AMERICA: OTHER PET APPLICATIONS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 127
TABLE 46 NORTH AMERICA: THERAPEUTIC APPLICATION MARKET,
2010 – 2017 ($MILLION) 128
TABLE 47 NORTH AMERICA: RADIOPHARMACEUTICALS THERAPEUTIC
APPLICATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 129
TABLE 48 NORTH AMERICA: RADIOPHARMACEUTICALS THYROID APPLICATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 130
TABLE 49 NORTH AMERICA: RADIOPHARMACEUTICALS BONE METASTASIS APPLICATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 131
TABLE 50 NORTH AMERICA: RADIOPHARMACEUTICALS LYMPHOMA APPLICATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 133
TABLE 51 NORTH AMERICA: RADIOPHARMACEUTICALS ENDOCRINE APPLICATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 134
TABLE 52 NORTH AMERICA: RADIOPHARMACEUTICALS OTHER APPLICATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 135
TABLE 53 NORTH AMERICA: STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION) 141
TABLE 54 NORTH AMERICA: STABLE ISOTOPE MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 143
TABLE 55 NORTH AMERICA: CARBON STABLE ISOTOPE MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 144
TABLE 56 NORTH AMERICA: DEUTERIUM STABLE ISOTOPE MARKET,
BY COUNTRY, 2010 – 2017 ($MILLION) 145
TABLE 57 NORTH AMERICA: OXYGEN STABLE ISOTOPE MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 146
TABLE 58 NORTH AMERICA: NITROGEN STABLE ISOTOPE MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 147
TABLE 59 NORTH AMERICA: OTHER STABLE ISOTOPE MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 148
TABLE 60 NORTH AMERICA: ENRICHED STABLE ISOTOPE MARKET,
FOR APPLICATION, 2010 – 2017 ($MILLION) 149
TABLE 61 NORTH AMERICA: STABLE ISOTOPES MARKET FOR DIAGNOSTIC & THERAPY APPLICATIONS, BY COUNTRY, 2010 – 2017 ($MILLION) 150
TABLE 62 NORTH AMERICA: STABLE ISOTOPES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2010 – 2017 ($MILLION) 151
TABLE 63 NORTH AMERICA: STABLE ISOTOPES MARKET FOR PHARMACEUTICAL APPLICATIONS, BY COUNTRY, 2010 – 2017 ($MILLION) 152
TABLE 64 NORTH AMERICA: STABLE ISOTOPES MARKET FOR INDUSTRIAL APPLICATIONS, BY COUNTRY, 2010 – 2017 ($MILLION) 153
TABLE 65 NORTH AMERICA: DIAGNOSTIC RADIOPHARMACEUTICALS MARKET,
BY TECHNOLOGY, 2010 – 2017 ($MILLION) 156
TABLE 66 NORTH AMERICA: SPECT RADIOPHARMACEUTICALS MARKET,
BY COUNTRY, 2010 – 2017 ($MILLION) 156
TABLE 67 NORTH AMERICA: SPECT RADIOPHARMACEUTICALS MARKET,
BY ISOTOPE, 2010 – 2017 ($MILLION) 157
TABLE 68 NORTH AMERICA: PET RADIOPHARMACEUTICALS MARKET,
BY COUNTRY, 2010 – 2017 ($MILLION) 158
TABLE 69 NORTH AMERICA: PET RADIOPHARMACEUTICALS MARKET,
BY ISOTOPE, 2010 – 2017 ($MILLION) 158
TABLE 70 NORTH AMERICA: THERAPEUTIC RADIOPHARMACEUTICALS MARKET, 2010 – 2017 ($MILLION) 159
TABLE 71 NORTH AMERICA: BETA EMITTERS MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 160
TABLE 72 NORTH AMERICA: BETA EMITTERS MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 161
TABLE 73 NORTH AMERICA: BRACHYTHERAPY MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 162
TABLE 74 NORTH AMERICA: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 163
TABLE 75 NORTH AMERICA: STABLE ISOTOPES MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 164
TABLE 76 NORTH AMERICA: STABLE ISOTOPES MARKET, 2010 – 2017 ($MILLION) 165
TABLE 77 NORTH AMERICA: STABLE ISOTOPES MARKET, BY APPLICATION,
2010 – 2017 ($MILLION) 166
TABLE 78 U.S.: DIAGNOSTIC RADIOPHARMACEUTICALS MARKET,
BY TECHNOLOGY, 2010 – 2017 ($MILLION) 168
TABLE 79 U.S.: SPECT RADIOPHARMACEUTICALS MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 169
TABLE 80 U.S.: PET RADIOPHARMACEUTICALS MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 170
TABLE 81 U.S.: THERAPEUTIC RADIOPHARMACEUTICALS MARKET,
2010 – 2017 ($MILLION) 171
TABLE 82 U.S.: BRACHYTHERAPY MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 172
TABLE 83 U.S.: BETA EMITTER MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 173
TABLE 84 U.S.: STABLE ISOTOPES MARKET, 2010 – 2017 ($MILLION) 174
TABLE 85 CANADA: DIAGNOSTIC RADIOPHARMACEUTICALS MARKET,
BY TECHNOLOGY, 2010 – 2017 ($MILLION) 176
TABLE 86 CANADA: SPECT RADIOPHARMACEUTICALS MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 177
TABLE 87 CANADA: PET RADIOPHARMACEUTICALS MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 178
TABLE 88 CANADA: THERAPEUTIC RADIOPHARMACEUTICALS MARKET,
2010 – 2017 ($MILLION) 179
TABLE 89 CANADA: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 180
TABLE 90 CANADA: BETA EMITTER MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 181
TABLE 91 CANADA: STABLE ISOTOPES MARKET, 2010 – 2017 ($MILLION) 182
TABLE 92 MERGERS & ACQUISITIONS, 2010 – 2012 184
TABLE 93 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES, 2010 – 2013 185
TABLE 94 PRODUCTS LAUNCH, 2010 – 2013 189
TABLE 95 EXPANSION, 2010 – 2012 190
TABLE 96 OTHER DEVELOPMENTS, 2010 – 2012 192
TABLE 97 APPROVALS, 2010 – 2012 194
TABLE 98 CAMBRIDGE ISOTOPE LABORATORIES INC.: TOTAL REVENUE,
BY SEGMENT, 2010 – 2012 ($MILLION) 198
TABLE 99 CAMBRIDGE ISOTOPE LABORATORIES INC.: TOTAL REVENUE,
BY GEOGRAPHY, 2010 – 2012 ($MILLION) 199
TABLE 100 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY SEGMENT,
2010 – 2012 ($MILLION) 202
TABLE 101 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012 ($MILLION) 203
TABLE 102 COVIDIEN, PLC: TOTAL REVENUE AND R&D EXPENDITURE,
2010 – 2012 ($MILLION) 209
TABLE 103 COVIDIEN, PLC: TOTAL REVENUE, BY SEGMENT,
2010 – 2012 ($MILLION) 209
TABLE 104 COVIDIEN, PLC: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012 ($MILLION) 211
TABLE 105 FUJIFILM HOLDINGS CORP: TOTAL REVENUE, BY SEGMENT,
2010 – 2012 ($MILLION) 217
TABLE 106 FUJIFILM HOLDINGS CORP: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012 ($MILLION) 217
TABLE 107 GENERAL ELECTRIC COMPANY: TOTAL REVENUE, BY SEGMENT,
2009 – 2011 ($BILLION) 221
TABLE 108 GENERAL ELECTRIC COMPANY: TOTAL REVENUE, BY GEOGRAPHY,
2009 – 2011 ($BILLION) 222
TABLE 109 IBA GROUP: MARKET REVENUE, BY SEGMENT,
2009 – 2011 ($MILLION) 226
TABLE 110 IBA GROUP: TOTAL REVENUE, BY GEOGRAPHY,
2009 – 2011 ($MILLION) 227
TABLE 111 ISOTEC INC.: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION) 232
TABLE 112 ISOTEC INC.: TOTAL REVENUE, BY GEOGRAPHY,
2009 – 2011 ($MILLION) 233
TABLE 113 LANTHEUS: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION) 237
TABLE 114 LANTHEUS: TOTAL REVENUE, BY GEOGRAPHY,
2009 – 2011 ($MILLION) 238
TABLE 115 NORDION, INC.: TOTAL REVENUE, BY SEGMENT,
2010 – 2012 ($MILLION) 245
TABLE 116 NORDION, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2017 245
TABLE 117 SIEMENS AG: TOTAL REVENUE AND R&D EXPENSES,
2010 – 2012 ($MILLION) 254
TABLE 118 SIEMENS AG: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION) 254
TABLE 119 SIEMENS AG: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012 ($MILLION) 255
TABLE 120 TAIYO NIPPON SANSO, CORP.: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012 ($MILLION) 259

LIST OF FIGURES

FIGURE 1 NORTH AMERICAN RADIOPHARMACEUTICALS MARKET, BY SEGMENT, 2010 – 2017 34
FIGURE 2 NORTH AMERICA STABLE ISOTOPES MARKET, $MILLION (2012 – 2017) 36
FIGURE 3 EVOLUTION OF RADIOPHARMACEUTICALS 39
FIGURE 4 RADIOPHARMACEUTICALS MARKET SEGMENTATION 40
FIGURE 5 ENRICHED STABLE ISOTOPES MARKET SEGMENTATION 41
FIGURE 6 MARKET DYNAMICS 42
FIGURE 7 SUPPLY CHAIN OF MO-99/TC-99M BETWEEN U.S. AND CANADA 52
FIGURE 8 NORTH AMERICA: RADIOPHARMACEUTICALS MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2012 57
FIGURE 9 NORTH AMERICA ENRICHED STABLE ISOTOPE MARKET: MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2012 60
FIGURE 10 OPPORTUNITY MATRIX: NORTH AMERICAN DIAGNOSTIC RADIOPHARMACEUTICALS MARKET (2012) 64
FIGURE 11 SPECT RADIOPHARMACEUTICALS MARKET SHARE (2012) 65
FIGURE 12 PET RADIOPHARMACEUTICALS MARKET SHARE (2012) 76
FIGURE 13 OPPORTUNITY MATRIX: NORTH AMERICAN THERAPEUTIC RADIOPHARMACEUTICALS MARKET (2012) 86
FIGURE 14 RA-223 DECAY CHAIN 98
FIGURE 15 PORTER'S FIVE FORCES ANALYSIS FOR ALPHARADIN 101
FIGURE 16 SWOT ANALYSIS OF ALPHARADIN 102
FIGURE 17 NORTH AMERICA: DIAGNOSTIC RADIOPHARMACEUTICALS MARKET,
BY TECHNOLOGY & INDICATION (2012 – 2017) 115
FIGURE 18 KEY GROWTH STRATEGIES, 2010 – 2013 183
FIGURE 19 CAMBRIDGE ISOTOPE LABORATORIES INC.: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($BILLION) 198
FIGURE 20 CARDINAL HEALTH, INC.: TOTAL REVENUE, 2010 – 2012 ($BILLION) 202
FIGURE 21 COVIDIEN, PLC: RADIOPHARMACEUTICALS REVENUE,
2010 – 2012 ($BILLION) 210
FIGURE 22 FUJIFILM HOLDINGS CORP: TOTAL REVENUE AND R&D EXPENDITURE, 2010 – 2012 ($BILLION) 216
FIGURE 23 GENERAL ELECTRIC COMPANY: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($BILLION) 221
FIGURE 24 IBA GROUP: TOTAL MARKET REVENUE, 2009 – 2011 ($MILLION) 226
FIGURE 25 ISOTEC INC.: TOTAL REVENUE AND R&D EXPENSES,
2009 – 2011 ($BILLION) 232
FIGURE 26 LANTHEUS: TOTAL REVENUE AND R&D EXPENSES,
2009 – 2011 ($MILLION) 236
FIGURE 27 NORDION, INC.: TOTAL MARKET REVENUE, 2010 – 2012 ($BILLION) 244
FIGURE 28 TAIYO NIPPON SANSO, CORP.: TOTAL REVENUE AND R&D EXPENDITURE, 2010 – 2012 ($BILLION) 259
FIGURE 29 URENCO LIMITED: TOTAL MARKET REVENUE, 2009 – 2011, ($BILLION) 265

To order this report:
Medical_Imaging Industry:
North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Forecast to 2017

_________________________
Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 60

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.